Yuan M, Wilson I
Immunol Rev. 2024; 329(1):e13431.
PMID: 39731211
PMC: 11727448.
DOI: 10.1111/imr.13431.
Bruun T, Do J, Weidenbacher P, Utz A, Kim P
ACS Cent Sci. 2024; 10(10):1871-1884.
PMID: 39463836
PMC: 11503491.
DOI: 10.1021/acscentsci.4c00722.
Hu Y, Wu Q, Chang F, Yang J, Zhang X, Wang Q
NPJ Vaccines. 2024; 9(1):195.
PMID: 39438493
PMC: 11496711.
DOI: 10.1038/s41541-024-00997-8.
Ouyang W, Lv H, Liu W, Lei R, Mou Z, Pholcharee T
bioRxiv. 2024; .
PMID: 39257766
PMC: 11383711.
DOI: 10.1101/2024.08.30.610421.
Guerra D, Radic L, Brinkkemper M, Poniman M, van der Maas L, Torres J
Hum Vaccin Immunother. 2024; 20(1):2388344.
PMID: 39165108
PMC: 11340772.
DOI: 10.1080/21645515.2024.2388344.
A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates.
Cui L, Li T, Lan M, Zhou M, Xue W, Zhang S
iScience. 2024; 27(7):110208.
PMID: 39015149
PMC: 11251093.
DOI: 10.1016/j.isci.2024.110208.
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.
Cui L, Li T, Xue W, Zhang S, Wang H, Liu H
Viruses. 2024; 16(6).
PMID: 38932192
PMC: 11209230.
DOI: 10.3390/v16060900.
Engineering a SARS-CoV-2 vaccine targeting the RBD cryptic-face via immunofocusing.
Bruun T, Do J, Weidenbacher P, Kim P
bioRxiv. 2024; .
PMID: 38895327
PMC: 11185595.
DOI: 10.1101/2024.06.05.597541.
The D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2.
Yuan M, Wilson I
Vaccines (Basel). 2024; 12(5).
PMID: 38793718
PMC: 11126049.
DOI: 10.3390/vaccines12050467.
COVID-19 drug discovery and treatment options.
Chan J, Yuan S, Chu H, Sridhar S, Yuen K
Nat Rev Microbiol. 2024; 22(7):391-407.
PMID: 38622352
DOI: 10.1038/s41579-024-01036-y.
Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.
Wang Q, Li Z, Guo Y, Mellis I, Iketani S, Liu M
iScience. 2023; 26(11):108254.
PMID: 38026207
PMC: 10654603.
DOI: 10.1016/j.isci.2023.108254.
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.
Wang Q, Guo Y, Liu L, Schwanz L, Li Z, Nair M
Nature. 2023; 624(7992):639-644.
PMID: 37871613
DOI: 10.1038/s41586-023-06750-w.
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.
Liu L, Casner R, Guo Y, Wang Q, Iketani S, Chan J
Immunity. 2023; 56(10):2442-2455.e8.
PMID: 37776849
PMC: 10588992.
DOI: 10.1016/j.immuni.2023.09.003.
SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain.
Jiang J, Boughter C, Ahmad J, Natarajan K, Boyd L, Meier-Schellersheim M
Commun Biol. 2023; 6(1):953.
PMID: 37726484
PMC: 10509263.
DOI: 10.1038/s42003-023-05332-w.
SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain.
Jiang J, Boughter C, Ahmad J, Natarajan K, Boyd L, Meier-Schellersheim M
Res Sq. 2023; .
PMID: 37333174
PMC: 10275037.
DOI: 10.21203/rs.3.rs-2800118/v1.
Broadly neutralizing antibodies against COVID-19.
Zhou D, Ren J, Fry E, Stuart D
Curr Opin Virol. 2023; 61:101332.
PMID: 37285620
PMC: 10301462.
DOI: 10.1016/j.coviro.2023.101332.
An optimized thermodynamics integration protocol for identifying beneficial mutations in antibody design.
Sheng Z, Bimela J, Wang M, Li Z, Guo Y, Ho D
Front Immunol. 2023; 14:1190416.
PMID: 37275896
PMC: 10235760.
DOI: 10.3389/fimmu.2023.1190416.
Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method.
Dou Y, Xu K, Deng Y, Jia Z, Lan J, Xu X
Antib Ther. 2023; 6(2):76-86.
PMID: 37077472
PMC: 10108556.
DOI: 10.1093/abt/tbad002.
Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost.
Nair M, Ribeiro R, Wang M, Bowen A, Liu L, Guo Y
iScience. 2023; 26(4):106345.
PMID: 36925721
PMC: 9987605.
DOI: 10.1016/j.isci.2023.106345.
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
Huang K, Chen X, Mohapatra A, Nguyen H, Schimanski L, Tan T
Nat Commun. 2023; 14(1):311.
PMID: 36658148
PMC: 9852238.
DOI: 10.1038/s41467-023-35949-8.